Last updated: April 25, 2026
Actelion v. Mylan (D. Del.) 1:20-cv-00110-IMK: Litigation Summary and Patent-Centered Analysis
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., case number 1:20-cv-00110-IMK, is a Hatch-Waxman patent dispute filed in the US District Court for the District of Delaware that turns on whether Mylan’s proposed generic product infringes and/or avoids Actelion’s asserted patents for an Actelion-originated medicine. The case sits in the post-filing, post-pleadings phase typical of ANDA litigation, where infringement and invalidity arguments are litigated around claim construction, design-around positions, and asserted patent validity under novelty, nonobviousness, written description, enablement, and best mode.
What the docket posture supports: the case is framed to test the legal sufficiency of Mylan’s noninfringement and invalidity defenses against Actelion’s infringement theories, with the court’s key work usually landing on claim construction and infringement comparisons, then validity rulings keyed to prior art and the asserted disclosures.
What is the litigation’s procedural posture in 1:20-cv-00110-IMK?
Case identifiers
- Court: US District Court for the District of Delaware
- Case name: Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc.
- Case number: 1:20-cv-00110-IMK
Procedural posture (what it typically means for business and R&D)
- ANDA-based patent dispute structure: The dispute is structured around the infringement of asserted patents listed in Orange Book against a generic applicant’s ANDA carve-in (or paragraph IV) positioning. The practical outcome is a statutory timing outcome tied to whether the asserted claims are found infringed and not invalid.
- Claim construction as the first major gate: In this case type, claim construction drives both infringement mapping and most validity analyses that depend on claim scope.
- Infringement and invalidity are litigated in parallel: Mylan’s defenses typically include noninfringement (literal infringement and doctrine of equivalents) and invalidity (anticipation/obviousness and specification-based grounds).
- Claim-by-claim comparison is the core record: The case’s fact development typically centers on the generic formulation, the labeling/indications, and the claim limitations at issue.
Business read-through
- If the court construes claims narrowly, Actelion’s infringement case often becomes more constrained.
- If the court construes broadly or credits equivalents, Mylan’s noninfringement positions usually face higher risk.
- If prior art is found to disclose key claim limitations or renders them obvious, Mylan’s invalidity posture tends to control the commercial timing regardless of infringement.
What patents and claims are at issue?
This analysis cannot identify the specific asserted patents, their numbers, expiration dates, or the specific claim set without making claims about the record that are not present in the provided input.
What can be stated from the case caption and type: Actelion’s asserted patent(s) are being used to enjoin Mylan’s ANDA launch unless the claims are found not infringed or invalid.
What legal issues decide the outcome?
How does the court decide infringement?
In an ANDA patent case in Delaware, the court generally evaluates:
- Literal infringement: Whether Mylan’s proposed product meets every limitation of each asserted claim.
- Doctrine of equivalents: Whether differences are insubstantial relative to claim limitations (if literal infringement fails).
- OTC or labeling-anchored limitations (if applicable): If claims require a dosing regimen, method of treatment, or patient selection element, infringement analysis will track the ANDA labeling and proposed prescribing use.
Practical implication: infringement is usually won or lost based on the claim-construction outcome and how the generic design maps to the construed claim elements.
How does the court decide invalidity?
Mylan’s invalidity case typically targets:
- Anticipation: A single reference discloses all features of the claim.
- Obviousness: A combination of references renders the claim obvious to a POSA.
- Written description and enablement: Whether the patent specification supports the full scope of the asserted claims and teaches making/using the invention.
- Best mode: If raised, whether the specification discloses the best mode contemplated at filing (often a secondary argument in modern practice).
Practical implication: validity is often the higher-probability control mechanism for ANDA launch timing when the prior art record is strong.
What is the strategic risk profile for Actelion vs. Mylan?
Actelion risk drivers
- Narrow claim construction that removes functional or structural coverage that Mylan’s proposed generic does not meet.
- Prior art overlap that attacks novelty or obviousness of core claim limitations.
- Specification attacks that reduce the claim’s effective breadth or invalidate for lack of support.
Mylan risk drivers
- Broad claim constructions that pull Mylan’s proposed formulation into the claim scope.
- Weak design-around facts where Mylan cannot show a stable noninfringement gap for each asserted limitation.
- Prior art gaps where the court rejects anticipation/obviousness combinations.
What are the business implications of an ANDA injunction or non-injunction?
For Actelion:
- A successful infringement/non-invalidity finding preserves market exclusivity leverage and blocks launch during the statutory window or through damages and licensing positions.
- A validity win for Mylan typically accelerates launch timing and compresses pricing and volume expectations.
For Mylan:
- A noninfringement or invalidity win enables launch and shifts Actelion to post-launch damages and/or separate enforcement against other entrants.
- Partial outcomes are possible: courts sometimes sustain some claims and strike others, leaving staged injunction or launch with a design-around.
What does this case signal about Actelion’s patent enforcement posture?
Without the asserted patent identification and the court’s substantive rulings, the only defensible signal is procedural: Actelion chose to litigate against Mylan in Delaware under the Hatch-Waxman framework, indicating:
- Actelion listed patents in Orange Book tied to its marketed product(s).
- Mylan pursued an ANDA path that triggered patent litigation, implying Actelion viewed at least one asserted patent as potentially enforceable at the outset.
Key Takeaways
- Actelion v. Mylan (1:20-cv-00110-IMK) is an ANDA Hatch-Waxman patent dispute in the District of Delaware that hinges on claim construction, infringement mapping, and validity challenges.
- Outcome is driven by how the court construes the asserted claim limitations and whether Mylan’s prior art and specification-based invalidity arguments survive.
- The business effect of the case is launch timing and market exclusivity protection, with damages and ongoing patent enforcement typically following the court’s claim-by-claim results.
FAQs
1) What court and case number is this?
US District Court for the District of Delaware, 1:20-cv-00110-IMK.
2) What is the legal framework of the dispute?
A Hatch-Waxman (ANDA) patent litigation where the generic applicant contests infringement and invalidity of asserted Actelion-listed patents.
3) What usually decides the outcome in this case type?
Claim construction first, then infringement and invalidity on a claim-by-claim basis.
4) What does a finding of noninfringement mean commercially?
It typically clears the path for ANDA launch unless other asserted patents block launch.
5) What does a finding of invalidity mean commercially?
It typically accelerates generic entry by removing the statutory basis for an injunction tied to the invalidated claims.
References
[1] US District Court for the District of Delaware, Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Case No. 1:20-cv-00110-IMK.
